Please use a PC Browser to access Register-Tadawul
Get It
Stock Ratings | Potential for a 195% Profit! HC Wainwright & Co. maintains its "Buy" recommendation on Nektar Therapeutics (NKTR) with a $165 price target.
Nektar Therapeutics -4.87%
Praxis Precision Medicines +1.54%
Microbot Medical Inc -1.58%
Aprea Therapeutics -0.89%
Evommune, Inc. -0.68%
Nektar Therapeutics NKTR | 69.76 | -4.87% |
Praxis Precision Medicines PRAX | 301.54 | +1.54% |
Microbot Medical Inc MBOT | 2.81 | -1.58% |
Aprea Therapeutics APRE | 0.78 | -0.89% |
Evommune, Inc. EVMN | 23.24 | -0.68% |
The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.
Risk warning:
Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.
Today's key assessments and concerns
HC Wainwright & Co.: Maintaining a "buy" rating on Nektar Therapeutics ( Nektar Therapeutics(NKTR.US) ), with a price target raised from $135 to $165.
BTIG: Maintaining a "Buy" rating on Nektar Therapeutics Nektar Therapeutics(NKTR.US) ), with a price target raised from $118 to $151
Guggenheim: Maintaining a "buy" rating on Praxis Precision Medicine ( Praxis Precision Medicines, Inc.(PRAX.US) ), while raising its price target from $760 to $800.
B. Riley Securities: Initial rating for Microbot Medical ( Microbot Medical Inc(MBOT.US) ) at "Buy", with a target price of $5.
Wedbush: Maintaining Aprea Therapeutics(APRE.US) ' rating at "Outperform Market", while lowering the price target from $11 to $7.
| Investment goal | Classification | Target price | Current price | Percentage of potential increase/decrease | (Classification) Agency |
| Nektar Therapeutics(NKTR.US) | to lift | $165.0 | $56.0 | 194.64% | HC Wainwright & Co. |
| Nektar Therapeutics(NKTR.US) | to lift | $151.0 | $56.0 | 169.64% | BTIG |
| Praxis Precision Medicines, Inc.(PRAX.US) . | to lift | $800.0 | $320.48 | 149.63% | Guggenheim |
| Evommune, Inc.(EVMN.US) | to lift | $65.0 | $29.03 | 123.91% | HC Wainwright & Co. |
| Amylyx Pharmaceuticals, Inc.(AMLX.US) | to lift | $28.0 | $14.89 | 88.05% | HC Wainwright & Co. |
| Microbot Medical Inc(MBOT.US) | Initial classification | $5.0 | $2.05 | 143.9% | B. Riley Securities |
| Aprea Therapeutics(APRE.US) | cut | $7.0 | $0.64 | 993.75% | Wedbush |
| REGENXBIO, Inc.(RGNX.US) | cut | $50.0 | $8.85 | 464.97% | Chardan Capital |
| REGENXBIO, Inc.(RGNX.US) | cut | $32.0 | $8.85 | 261.58% | HC Wainwright & Co. |
| Alight, Inc. Class A(ALIT.US) | cut | $5.0 | $1.51 | 231.13% | DA Davidson |
comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)
Lifting
B of A Securities: Maintaining a "buy" rating on AECOM ( AECOM(ACM.US) ), while raising the price target from $117 to $118.
UBS: Maintaining a "buy" rating on AECOM ( AECOM(ACM.US) ), while raising the price target from $143 to $145.
Barclays: Maintaining an "overweight" rating on Grupo Aeromexico ( Grupo Aeromexico, S.A.B. de C.V. Unsponsored ADR(AERO.US) ), while raising the price target from $27 to $28.
Citigroup: Maintaining a "neutral" rating on Allstate Allstate Corporation(ALL.US) ) stock, while raising its price target from $216 to $221.
First Coverage
B. Riley Securities: Initial rating for Microbot Medical ( Microbot Medical Inc(MBOT.US) ) stock at "Buy", with a target price of $5.
Roth Capital: Initial rating for Orion Group Holdings ( Orion Group Holdings, Inc.(ORN.US) ) at "Buy", with a target price of $17.
reduction
DA Davidson: Maintaining a "buy" rating on Alight ( Alight, Inc. Class A(ALIT.US) ) stock, while lowering the price target from $6 to $5.
Barclays: Maintaining its "Overweight" rating on Apollo Global Management Apollo Global Management Inc(APO.US) , while lowering its price target from $168 to $158.
UBS: Maintaining a "buy" rating on AppLovin ( AppLovin(APP.US) ), while lowering its price target from $840 to $686.
Wedbush: Maintaining Aprea Therapeutics(APRE.US) ' rating at "Outperform Market", while lowering the price target from $11 to $7.
Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk Warning: Investing involves risk. Securities may rise, fall, or become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.
